BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2020 10:31:56 AM | Browse: 541 | Download: 416
 |
Received |
|
2020-02-26 15:19 |
|
Peer-Review Started |
|
2020-02-26 15:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-04 10:48 |
|
Revised |
|
2020-04-18 13:20 |
|
Second Decision |
|
2020-05-12 08:36 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-05-13 06:26 |
|
Articles in Press |
|
2020-05-13 06:26 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-05-29 01:43 |
|
Typeset the Manuscript |
|
2020-06-23 09:11 |
|
Publish the Manuscript Online |
|
2020-06-24 10:31 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Minireviews |
| Article Title |
Progress in immunotherapy for small cell lung cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dong Zhao, Bing Xie, Yong Yang, Peng Yan, Sheng-Nan Liang and Qiang Lin |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com |
| Key Words |
Small-cell lung cancer; Programmed death-1 inhibitors; Cytotoxic T lymphocyte-associated antigen-4 inhibitors; Poly adenosine diphosphate ribose polymerase inhibitors; ; |
| Core Tip |
Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. Classical radiotherapy and chemotherapy have a plateauing effect. Immunotherapy is becoming an important treatment strategy for SCLC. In this article we review the recent advances in immunotherapy for SCLC. |
| Publish Date |
2020-06-24 10:31 |
| Citation |
Zhao D, Xie B, Yang Y, Yan P, Liang SN, Lin Q. Progress in immunotherapy for small cell lung cancer. World J Clin Oncol 2020; 11(6): 370-377 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i6/370.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i6.370 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
